Drive growth and adoption of Crown's extensive in vitro and in vivo Oncology service portfolio with Boston area clients. Offerings include cell based screening, xenograft and PDX models, as well as advanced immuno-oncology platforms including thoroughly characterized syngeneic models, MuPrime GEMM allografts, HuGEMM chimeric human checkpoint knock in models and humanized mouse models.

Responsible for revenue growth and business development for clients in New England and the upper Midwest. Crown Bioscience, Inc. is a Preclinical CRO with expertise in Oncology and Metabolic Disease. We are known for the breadth and quality of our patient-relevant in vitro and in vivo disease models, as well as our ability to help clients quantify the efficacy and pharmacological profiles of their candidate molecules before they move them into the clinic. Our unique collection of ready-to-run, well-validated in vitro and in vivo models, model development expertise, comprehensive drug discovery platforms and global capacity enable us to deliver the results our clients need today.

Responsible for revenue growth and all business development opportunities on the East Coast for Patient-Derived Xenograft Oncology Models for pre-clinical in vivo pharmacology and biomarker studies.

Responsible for all sales and business development activities in North America. Coach, mentor, and manage an East Coast and a West Coast based Business Development Manager while directly selling to large pharmaceutical and biotech accounts in the Northeast. Achieved 110% of aggressive double digit annual growth target through August 2013.

Business development for preclinical cardiac safety assay services, ion channel & GPCR screening services as well as cell line products to Biopharmaceutical customers.